Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

CareDx to Present New AlloSure® Data at American Society of Transplant Surgeons Winter Symposium

GlobeNewswire Wednesday, 9 January 2019
AlloSure utility studied in patients with delayed graft function

BRISBANE, Calif., Jan. 09, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that the company will be presenting data highlighting the AlloSure test and hosting a lunch symposium at the American Society of Transplant Surgeons (ASTS) 19th Annual State of the Art Winter Symposium in Miami, Florida, from January 10 – 13.CareDx will be sponsoring a lunch symposium on Friday, January 11^th, from 11:00 a.m. – 12:30 p.m. ET, entitled, Modernizing the Care of Kidney Transplant Patients with AlloSure. AlloSure is the first donor-derived cell-free DNA test to assess allograft health, and is broadly available to transplant patients.

The two keynote speakers, Steve Potter, M.D., transplant surgeon at Baylor, Scott & White Health, and Stanley Jordan, M.D., Director of the Nephrology Division at Cedars-Sinai Comprehensive Transplant Center, will share their experiences using AlloSure to assist in management of post-transplant patients. Together with Sham Dholakia, M.D., DPhil, Medical Director, CareDx, Inc., they will present examples of AlloSure patient cases, discuss best ways to surveil kidney transplant recipients for graft health, and to personalize their care.

In addition, an abstract titled “Donor-derived cell-free DNA in renal transplant recipients with delayed graft function” will be presented during the ASTS poster session on Thursday, January 10, from 5:45 – 7:15 pm. This study demonstrates that many patients with delayed graft function (DGF) exhibit elevated AlloSure levels immediately following their transplant, and for up to two years.

“Our research suggests that measuring dd-cfDNA via AlloSure may help identify the subset of DGF patients at risk early on, and allow more timely and effective interventions,” commented Daniel C. Brennan, M.D. Medical Director, Comprehensive Transplant Center, Johns Hopkins Hospital.

“We are excited to partner with the American Society of Transplant Surgeons (ASTS) and present these exciting new results, which continue to strengthen the clinical utility of AlloSure. We are committed to transforming transplant care by working with leading physicians and scientists, and addressing unmet needs in the field,” says James Yee, M.D., Ph.D., Chief Medical Officer, CareDx, Inc.

Additional information and resources on CareDx, Inc. and CareDx products will also be available at the CareDx booth #23/24.

*About** CareDx*
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum.

For more information, please visit: www.CareDx.com.

*CONTACTS:*
Media Relations
Amy Wheeler
Lazar Partners
646-871-8486
awheeler@lazarpartners.com

Investor Relations
David Clair
Integrated Corporate Relations, Inc.
646-277-1266
david.clair@icrinc.com
0
shares
ShareTweetSavePostSend
 

You Might Like


Recent related news from verified sources

Orchard Therapeutics Announces Acceptance of Late-Breaking Abstracts of OTL-101 for ADA-SCID and OTL-102 for X-CGD at the 2019 Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR

BOSTON and LONDON, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to...
GlobeNewswire

Myriad to Present New Data for Its Expanded Carrier and Noninvasive Prenatal Screens at the 2019 Society for Maternal-Fetal Medicine Annual Meeting

SALT LAKE CITY, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and personalized medicine, today...
GlobeNewswire


Tweets about this


Other recent news in Press Releases

AUSTRALIA's First Kafnu To Open in SydneyCyient Recognized as a "Major Contender" in Everest Group's PEAK Matrix(TM): Medical Device ENGINEERING Services Assessment 2019
Mensch und Maschine SOFTWARE SE discloses preliminary 2018 figuresHow Affordable CAR INSURANCE for High-Risk Drivers Can Be Obtained With The Help Of Several Smart Methods
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Contact us  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest